Gemina Laboratories Ltd. (CSE:GLAB)

Market Cap	62.02M
Revenue (ttm)	n/a
Net Income (ttm)	-4.07M
Shares Out	76.57M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Average Volume	2,250
Open	0.7800
Previous Close	0.7800
Day's Range	0.7800 - 0.7800
52-Week Range	0.2800 - 1.2500
Beta	0.58
RSI	32.41
Earnings Date	May 30, 2025

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: GLAB